奎扎替尼
奎扎替尼 | |
---|---|
IUPAC名 N-(5-tert-Butyl-1,2-oxazol-3-yl)-N′-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea | |
别名 |
|
识别 | |
CAS号 | 950769-58-1 [PubChem] |
PubChem | 24889392 |
ChemSpider | 24640357 |
SMILES |
|
InChI |
|
InChIKey | CVWXJKQAOSCOAB-UHFFFAOYAF |
ChEBI | 90217 |
DrugBank | DB12874 |
KEGG | D09955 |
IUPHAR配体 | 5658 |
性质 | |
化学式 | C29H32N6O4S |
摩尔质量 | 560.67 g·mol−1 |
药理学 | |
ATC代码 | L01EX11(L01) |
药品分级 | |
若非注明,所有数据均出自标准状态(25 ℃,100 kPa)下。 |
奎扎替尼(Quizartinib)是一种用于治疗急性骨髓性白血病的药物,商品名为Vanflyta。[2]
它是一种小分子受体酪氨酸激酶抑制剂。其分子靶点是FLT3,也称CD135(一种原癌基因)。[3]
它在2019年10月在日本获许使用,[4]2023年7月在美国得到批准。[2]
参考文献
- ^ Vanflyta- quizartinib tablet, film coated. DailyMed. 26 July 2023 [6 August 2023]. (原始内容存档于7 August 2023).
- ^ 2.0 2.1 2.2 FDA approves quizartinib for newly diagnosed acute myeloid leukemia. U.S. Food and Drug Administration (FDA). 20 July 2023 [21 July 2023]. (原始内容存档于21 July 2023). 本文含有此來源中屬於公有领域的内容。
- ^ Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, et al. Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. Journal of Medicinal Chemistry. December 2009, 52 (23): 7808–7816. PMID 19754199. doi:10.1021/jm9007533.
- ^ Daiichi Sankyo Launches FLT3 Inhibitor Vanflyta in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML (新闻稿). [16 February 2021]. (原始内容存档于2023-08-10).
外部链接
- Clinical trial number NCT02668653 for "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)" at ClinicalTrials.gov